TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8907785

Group type: EXPERIMENTAL
Intervention: Nicotine patch
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nicotine gum
Number of subjects: 0
Study: 1859044

Group type: EXPERIMENTAL
Intervention: 50 mg of oral prednisone 13, 7, and 1 hour before and 50 mg intramuscular diphenhydramine 1 hour before procedures (group I)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: 300 mg oral cimetidine one hour before procedure in addition to the other regimen (group II)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: 50 mg of oral prednisone, 300 mg oral cimetidine, and 25 mg oral ephedrine one hour before procedures (group III)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Provocative dosing regimen in a separate group of ten patients whose previous reactions to RCM were life threatening (shock)
Number of subjects: 149
Study: 30964964

Group type: EXPERIMENTAL
Intervention: G2‐E4 (ESWT at 4 weeks)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: G3‐E8 (ESWT at 8 weeks)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: G4‐E16 (ESWT at 16 weeks)
Number of subjects: 36

Group type: COMPARATOR
Intervention: G1‐S (sham ESWT)
Number of subjects: 36
Study: 28237629

Group type: EXPERIMENTAL
Intervention: 2% chlorhexidine digluconate (CHX)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo solution
Number of subjects: 42
Study: 25873233

Group type: EXPERIMENTAL
Intervention: 3D fluoroscopy-based navigation combined with conventional fluoroscopy (NAV group)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional fluoroscopy (FLUORO group)
Number of subjects: 40
Study: 23174629

Group type: EXPERIMENTAL
Intervention: Life coaching and pharmacist counseling
Number of subjects: 190

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Life coaching and pharmacist counseling (greater number of sessions)
Number of subjects: 190
Study: 21332635

Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 gel (1- or 2-mg Prostin E2 vaginal gel)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 gel
Number of subjects: 165

Group type: COMPARATOR
Intervention: Prostaglandin E2 tablets (3-mg Prostin E2 vaginal tablets)
Number of subjects: 165
Study: 18992272

Group type: EXPERIMENTAL
Intervention: Transient activation (flash suppression)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sustained activation (binocular rivalry)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Computational modeling
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Contralateral surround activation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Onset of contralateral surround
Number of subjects: 0
Study: 18834620

Group type: EXPERIMENTAL
Intervention: Robotic-assisted laparoscopic hysterectomy (RALH) with lymphadenectomy (LA)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Total abdominal hysterectomy (TAH) with lymphadenectomy (LA)
Number of subjects: 162
Study: 15921508

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 796

Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 796

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 796

Group type: EXPERIMENTAL
Intervention: Antipsychotic polypharmacy
Number of subjects: 796

Group type: EXPERIMENTAL
Intervention: Monotherapy
Number of subjects: 796

Group type: COMPARATOR
Intervention: Overall treatment
Number of subjects: 796
Study: 12243012

Group type: EXPERIMENTAL
Intervention: Palacos mixed in vacuum
Number of subjects: 72

Group type: COMPARATOR
Intervention: Palacos mixed conventionally (Control)
Number of subjects: 72
Study: 10416052

Group type: EXPERIMENTAL
Intervention: Ubiquinone (Q10) 90 mg/day
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Ubiquinone (Q10) 180 mg/day
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study: 7589772

Group type: EXPERIMENTAL
Intervention: SCMC‐Lys 900 mg three times a day (adults) or SCMC‐Lys 270 mg three times a day (children)
Number of subjects: 26

Group type: COMPARATOR
Intervention: ABX 33 mg three times a day (adults) or ABX 10 mg four times a day (children)
Number of subjects: 26
Study: 1693042

Group type: EXPERIMENTAL
Intervention: Tyrosine (0.3 g/kg) and Tryptophan (0.1 g/kg) for 2 to 17 weeks
Number of subjects: 9

Group type: COMPARATOR
Intervention: Double-blind cross-over trial
Number of subjects: 9
Study: 7251235

Group type: EXPERIMENTAL
Intervention: Palerol
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Litalgin
Number of subjects: 19
Study: 31739785

Group type: EXPERIMENTAL
Intervention: Information leaflet on fever and management of fever in children
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no information leaflet)
Number of subjects: 100
Study: 28091362

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Viaskin Peanut 100 μg (VP100)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Viaskin Peanut 250 μg (VP250)
Number of subjects: 74
Study: 26054865

Group type: EXPERIMENTAL
Intervention: Spacer injection (SpaceOAR system)
Number of subjects: 222

Group type: COMPARATOR
Intervention: Control (no injection)
Number of subjects: 222
Study: 23365108

Group type: EXPERIMENTAL
Intervention: Whole-berry purée with white bread (WB)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Whole-berry purée with rye bread (RB)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Strawberries with WB
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Berry mixture with WB
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Berry mixture with RB
Number of subjects: 20

Group type: COMPARATOR
Intervention: WB without berries (reference)
Number of subjects: 20

Group type: COMPARATOR
Intervention: RB without berries (reference)
Number of subjects: 20
Study: 20979541

Group type: EXPERIMENTAL
Intervention: Morning administration of 60 mg dry soy seed extract (glycine max) with 40% total isoflavones, primrose oil, and α‐tocopherol
Number of subjects: 1682

Group type: EXPERIMENTAL
Intervention: Evening administration of 60 mg dry soy seed extract (glycine max) with 40% total isoflavones, primrose oil, and α‐tocopherol
Number of subjects: 1682
Study: 19389471

Group type: EXPERIMENTAL
Intervention: Antioxidant vitamins C and E supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 17472864

Group type: EXPERIMENTAL
Intervention: Extended cycle combined hormonal contraception
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional cyclic combined hormonal contraception
Number of subjects: 0
Study: 15041615

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.1% with fentanyl 0.0002%
Number of subjects: 350

Group type: COMPARATOR
Intervention: Bupivacaine 0.1% with fentanyl 0.0002%
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Ropivacaine
Number of subjects: 350

Group type: COMPARATOR
Intervention: Bupivacaine
Number of subjects: 350
Study: 11586009

Group type: EXPERIMENTAL
Intervention: Topical metronidazole 1% vanishing cream
Number of subjects: 9

Group type: COMPARATOR
Intervention: Vehicle only
Number of subjects: 9

Group type: COMPARATOR
Intervention: Untreated (control)
Number of subjects: 9
Study: 9128234

Group type: EXPERIMENTAL
Intervention: Streamlined operating room supply pack
Number of subjects: 139

Group type: COMPARATOR
Intervention: Standard operating room supply pack (Control)
Number of subjects: 139

Group type: COMPARATOR
Intervention: Both groups (Streamlined and Control)
Number of subjects: 139
Study: 8201126

Group type: EXPERIMENTAL
Intervention: 30 mg D-fenfluramine
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 3322837

Group type: EXPERIMENTAL
Intervention: Madopar HBS (200 mg levodopa plus 50 mg benserazide)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Madopar HBS (3 capsules of 125 mg)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Standard Madopar (2 capsules of 125 mg)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Madopar HBS
Number of subjects: 17
Study: 31944252

Group type: EXPERIMENTAL
Intervention: Talus mobilization intervention (6 sessions of manual therapy)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Sham treatment (control group)
Number of subjects: 36
Study: 28818486

Group type: EXPERIMENTAL
Intervention: Counter-ads produced during media literacy lesson
Number of subjects: 40
Study: 27974055

Group type: EXPERIMENTAL
Intervention: Prebiotic (galacto-oligosaccharide mixture)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo (maltodextrin)
Number of subjects: 29
Study: 24256848

Group type: EXPERIMENTAL
Intervention: TPF-CCRT
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: PF-CCRT
Number of subjects: 439

Group type: COMPARATOR
Intervention: CCRT alone
Number of subjects: 439
Study: 23523116

Group type: EXPERIMENTAL
Intervention: 20mg AZD2423
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: 150mg AZD2423
Number of subjects: 133

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 133
Study: 20492735

Group type: EXPERIMENTAL
Intervention: SFA (saturated fatty acids)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: PUFA (polyunsaturated fatty acids)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: MUFA (monounsaturated fatty acids)
Number of subjects: 18
Study: 18491179

Group type: EXPERIMENTAL
Intervention: Topical BoNTA (CosmeTox) cream (2 U/ml)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo cream (without BoNTA)
Number of subjects: 40
Study: 15750370

Group type: EXPERIMENTAL
Intervention: True acupuncture on point P6 (Neiguan)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Placebo/sham acupuncture on a virtual point 1 cm proximal and lateral to P6
Number of subjects: 220
Study: 11834955

Group type: EXPERIMENTAL
Intervention: SF-12 Health Status Questionnaire
Number of subjects: 0

Group type: COMPARATOR
Intervention: SF-39 Health Status Questionnaire
Number of subjects: 0
Study: 10744129

Group type: EXPERIMENTAL
Intervention: 15 mg alpha-tocopherol per day
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: 60 mg alpha-tocopherol per day
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: 200 mg alpha-tocopherol per day
Number of subjects: 31
Study: 7730690

Group type: EXPERIMENTAL
Intervention: Dronabinol 2.5 mg twice daily
Number of subjects: 139

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 139
Study: 2389649

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25% scalp infiltration
Number of subjects: 20

Group type: COMPARATOR
Intervention: Normal saline scalp infiltration
Number of subjects: 20
Study: 7308334

Group type: EXPERIMENTAL
Intervention: OD treatment group (advice and medication for OD)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group (no treatment, advised to recheck OD in 2 months)
Number of subjects: 62
Study: 29363448

Group type: EXPERIMENTAL
Intervention: Enhanced variant of the UV program
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Basic variant of the UV program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control groups (no intervention)
Number of subjects: 0
Study: 26912555

Group type: EXPERIMENTAL
Intervention: Sirolimus (3 mg/d; serum target levels of 5‐10 ng/ml) added on to conventional therapy
Number of subjects: 41

Group type: COMPARATOR
Intervention: Conventional treatment alone
Number of subjects: 41
Study: 24246498

Group type: EXPERIMENTAL
Intervention: Quality of life (QoL) assessment in CMT1A patients
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Auditory dysfunction
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Carpal Tunnel Syndrome (CTS)
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Sleep apnoea
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Onset of symptoms
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Overall Neuropathy Limitation Scale
Number of subjects: 189
Study: 23489975

Group type: EXPERIMENTAL
Intervention: Peppermint oil (PO) 182 mg
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 20121647

Group type: EXPERIMENTAL
Intervention: Electronic prevention programme (EPP) installation
Number of subjects: 185

Group type: COMPARATOR
Intervention: Group education session or education via e-mail, telephone, or at home
Number of subjects: 185
Study: 18852339

Group type: EXPERIMENTAL
Intervention: Natalizumab
Number of subjects: 1
Study: 16188178

Group type: EXPERIMENTAL
Intervention: Finasteride 1 mg daily from 4 weeks before until 48 weeks after hair transplant
Number of subjects: 79

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study: 14511965

Group type: EXPERIMENTAL
Intervention: Pre-eclampsia and gestational hypertension
Number of subjects: 36

Group type: COMPARATOR
Intervention: Healthy pregnant controls
Number of subjects: 36
Study: 10801755

Group type: EXPERIMENTAL
Intervention: Intracoronary adenosine
Number of subjects: 54

Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 54
Study: 8973753

Group type: EXPERIMENTAL
Intervention: Bunazosin
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 174

Group type: COMPARATOR
Intervention: Comparison between Bunazosin and Atenolol
Number of subjects: 174
Study: 1405352

Group type: EXPERIMENTAL
Intervention: Plasmapheresis in severe SLE GN
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Chronicity Index (CI)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Activity Index (AI)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Receiver Operator Characteristics (ROC) analysis
Number of subjects: 86
Study: 3910260

Group type: EXPERIMENTAL
Intervention: Occlusal adjustment
Number of subjects: 91

Group type: COMPARATOR
Intervention: Placebo (mock occlusal adjustment)
Number of subjects: 91
Study: 30895506

Group type: EXPERIMENTAL
Intervention: Antral sparing (AS‐LSG)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Antral resection (AR‐LSG)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study: 29037769

Group type: EXPERIMENTAL
Intervention: Inspiratory Pressure Threshold Loading (IPTL)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Voluntary Isocapnic Hyperpnea (VIH)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Inspiratory Flow Resistive Loading (IFRL)
Number of subjects: 41
Study: 26678666

Group type: EXPERIMENTAL
Intervention: Aerobic exercise (AE) for 30 minutes at 40-60% intensity
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Aerobic exercise (AE)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group (CT)
Number of subjects: 19
Study: 26029989

Group type: EXPERIMENTAL
Intervention: Active device (Menopod®)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sham device
Number of subjects: 40
Study: 22719060

Group type: EXPERIMENTAL
Intervention: Riociguat 0.5 mg, 1 mg, or up to 2 mg three times daily (titrated for 8 weeks, followed by 8 weeks at stable dose)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 20150526

Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg daily
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg daily + Diltiazem 60 mg 3 times daily
Number of subjects: 30
Study: 18689558

Group type: COMPARATOR
Intervention: 0 mg lycopene/day (placebo)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: 6.5 mg lycopene/day
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: 15 mg lycopene/day
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: 30 mg lycopene/day
Number of subjects: 77
Study: 15927951

Group type: EXPERIMENTAL
Intervention: Room air
Number of subjects: 204

Group type: COMPARATOR
Intervention: 100 per cent oxygen
Number of subjects: 204
Study: 12708762

Group type: EXPERIMENTAL
Intervention: Leukocyte depletion with aprotinin
Number of subjects: 225

Group type: COMPARATOR
Intervention: Moderately hypothermic CPB alone (control group)
Number of subjects: 225
Study: 10584290

Group type: EXPERIMENTAL
Intervention: Allergen specific immunotherapy with birch and/or timothy pollen allergen extract
Number of subjects: 210

Group type: COMPARATOR
Intervention: Optimal pharmacotherapy (Control)
Number of subjects: 210
Study: 8803358

Group type: EXPERIMENTAL
Intervention: Sexual communication skills training
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Self-management skills training
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Combination of sexual communication and self-management skills
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: HIV education and risk sensitization
Number of subjects: 87
Study: 1794369

Group type: EXPERIMENTAL
Intervention: Single-dose ornidazole
Number of subjects: 75

Group type: COMPARATOR
Intervention: Seven-day metronidazole
Number of subjects: 75
Study: 6540178

Group type: EXPERIMENTAL
Intervention: Presence of residual cancer tissue (RCT)
Number of subjects: 3264

Group type: COMPARATOR
Intervention: Absence of residual cancer tissue (RCT)
Number of subjects: 3264
Study: 30694697

Group type: EXPERIMENTAL
Intervention: Dasotraline 4 mg/day
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: Dasotraline 2 mg/day
Number of subjects: 342

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 342
Study: 30006417

Group type: EXPERIMENTAL
Intervention: Intensive BP lowering (eGFR decline 5% to <20%)
Number of subjects: 1660

Group type: COMPARATOR
Intervention: Usual BP (eGFR decline 5% to <20%)
Number of subjects: 1660

Group type: EXPERIMENTAL
Intervention: Intensive BP lowering (eGFR decline ≥20%)
Number of subjects: 1660

Group type: COMPARATOR
Intervention: Usual BP (eGFR decline ≥20%)
Number of subjects: 1660
Study: 26121432

Group type: COMPARATOR
Intervention: Cluster sets (CLU) with 70% one repetition maximum, 4 × (2 × 5) with 30 seconds between clusters and 90 seconds between sets.
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Traditional sets (TRD) with 70% one repetition maximum, 4 × 10 with 120-second rest.
Number of subjects: 24
Study: 25270214

Group type: EXPERIMENTAL
Intervention: Xinfeng capsule (XFC), 3 tablets each time, tid, n=70
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Salicylazosulfapyridine (SASP), 4 pills each time, bid, n=70
Number of subjects: 140

Group type: COMPARATOR
Intervention: Healthy control group, n=60
Number of subjects: 140
Study: 20518806

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg QD for 12 weeks
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 20 mg QD for 12 weeks
Number of subjects: 209

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 209
Study: 16140092

Group type: EXPERIMENTAL
Intervention: Alarm monotherapy
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Desmopressin combined with alarm
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Imipramine combined with alarm
Number of subjects: 105
Study: 12387554

Group type: EXPERIMENTAL
Intervention: Adolescent Transitions Program (ATP) intervention
Number of subjects: 672

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 672
Study: 9432341

Group type: EXPERIMENTAL
Intervention: RBC400 + CLAR (Ranitidine bismuth citrate 400 mg bid with clarithromycin 250 mg qid for 14 days)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: RBC800 + CLAR (Ranitidine bismuth citrate 800 mg bid with clarithromycin 250 mg qid for 14 days)
Number of subjects: 95

Group type: COMPARATOR
Intervention: RBC400 (Ranitidine bismuth citrate 400 mg bid alone for 4 weeks)
Number of subjects: 95
Study: 7523450

Group type: EXPERIMENTAL
Intervention: 0.30 mg DEP nasal challenge
Number of subjects: 0
Study: 2452997

Group type: EXPERIMENTAL
Intervention: Midodrine (alpha-adrenergic agonist)
Number of subjects: 7
Study: 11737617

Group type: EXPERIMENTAL
Intervention: Iron management based on serum ferritin and transferrin saturation
Number of subjects: 157

Group type: COMPARATOR
Intervention: Iron management based on CHr
Number of subjects: 157
Study: 30830474

Group type: EXPERIMENTAL
Intervention: UDCA 400 mg daily for 2 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: UDCA 800 mg daily for 2 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: UDCA 1200 mg daily for 2 weeks
Number of subjects: 0
Study: 30474426

Group type: EXPERIMENTAL
Intervention: Higher circulating endostatin levels
Number of subjects: 1536

Group type: COMPARATOR
Intervention: Control group (age-, sex-, and cohort-matched)
Number of subjects: 1536
Study: 26749073

Group type: EXPERIMENTAL
Intervention: Fish oil (EPA + DHA; 8-10 g over 2-5 days preoperatively, then 2 g/day postoperatively)
Number of subjects: 479

Group type: COMPARATOR
Intervention: Placebo (olive oil)
Number of subjects: 479
Study: 24784512

Group type: EXPERIMENTAL
Intervention: Pressure-laminated (LM) mouthguards
Number of subjects: 412

Group type: COMPARATOR
Intervention: Over-the-counter (OTC) mouthguards
Number of subjects: 412
Study: 23167481

Group type: EXPERIMENTAL
Intervention: Pit and fissure sealants (PFS) applied at baseline and re-examined at 6, 12, 18, 24, and 30 months
Number of subjects: 920

Group type: COMPARATOR
Intervention: Fluoride varnish (FV) applied at baseline, 6, 12, 18, 24, and 30 months
Number of subjects: 920
Study: 19585071

Group type: COMPARATOR
Intervention: Blind basket procedure (group A)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Choledochoscopy‐assisted procedure (group B)
Number of subjects: 63
Study: 17392540

Group type: EXPERIMENTAL
Intervention: Glimepiride (1-8 mg once daily)
Number of subjects: 285

Group type: COMPARATOR
Intervention: Metformin (500-1000 mg twice daily)
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: Glimepiride
Number of subjects: 285

Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 285
Study: 15356074

Group type: EXPERIMENTAL
Intervention: rhIGF‐I/IGFBP‐3 (0.1 mg/kg.d)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: rhIGF‐I/IGFBP‐3 (0.4 mg/kg.d)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: rhIGF‐I/IGFBP‐3 (0.8 mg/kg.d)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 11591843

Group type: EXPERIMENTAL
Intervention: Pulsed IV methylprednisolone (IVMP) - 1 g/day for 5 days every 4 months for 3 years, then every 6 months for 2 years
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Pulsed IV methylprednisolone (IVMP)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Control group (IVMP only for relapses)
Number of subjects: 88
Study: 9727767

Group type: EXPERIMENTAL
Intervention: Pulmonary function tests and surgical interventions (aortopexy, tissue expander implantation, laser ablation)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Control group of nine term healthy neonates
Number of subjects: 2
Study: 8059023

Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin (rHuEpo) treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hemodialysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of hemodialysis and rHuEpo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 0